Check for updates





Blood 142 (2023) 5877-5879

The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

613.ACUTE MYELOID LEUKEMIAS: CLINICAL AND EPIDEMIOLOGICAL

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Patrizia Zappasodi, MD¹, Ludovica Calabretta², Davide Lazzarotto³, Marco Cerrano, MD⁴, Nicola Fracchiolla, MD⁵, Cristina Papayannidis, MD⁶, Monia Lunghi, MD PhD^{7,8}, Fabio Forghieri⁹, Elisa Buzzatti¹⁰, Michelina Dargenio, MD¹¹, Crescenza Pasciolla¹², Marzia Defina, MD¹³, Fabio Guolo, MDPhD^{14,15}, Carla Mazzone, MD¹⁶, Elisa Roncoroni¹⁷, Marianna Rossi, MD¹, Sabina Chiaretti, MD PhD¹⁸, Giovanni Pizzolo, MD^{19,20}, Robin Foà, MD²¹, Anna Candoni, MD²²

¹ Division of Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy, Pavia, ITA

²Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy, Pavia, Italy

³Clinica Ematologica e Unità di Terapie Cellulari Presidio Ospedaliero Santa Maria della Misericordia di Udine Azienda Sanitaria Universitaria Friuli Centrale, Udine, ITA

⁴ Division of Hematology, Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

⁵Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy

⁶ Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

⁷ Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy ⁸Amedeo Avogadro University of Eastern Piedmont, Novara, ITA

⁹Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda ospedaliero-universitaria di Modena Modena, Italy, Modena, ITA

¹⁰ Dipartimento di Biomedicina e Prevenzione, Università degli di studi di Roma Tor Vergata, Roma, Rome, Italy

¹¹ Divisione di Ematologia e Centro Trapianti, CSE Vito Lazzi, Lecce, Italy

¹²Ematologia, Istituto Tumori Giovanni Paolo II- Bari, Bari, Italy

¹³Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy

¹⁴IRCCS Ospedale Policlinico San Martino, Genoa, Italy

¹⁵Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy

¹⁶Hematology and Stem Cell Transplant Unit, St. Eugenio Hospital, Rome, ITA

¹⁷ Division of Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy, Pavia, Italy

¹⁸ Division of Hematology, Department of Translational and Precision Medicine, Division of Hematology, Rome, Italy
¹⁹ Department of Medicine, Hematology section, University of Verona, Verona, ITA

²⁰Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy

²¹ Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

²² Section of Hematology, Dept. of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Modena, Italy

Background The Italian national program of pediatric-inspired chemotherapy GIMEMA LAL1913 trial for adult Ph- acute lymphoblastic leukemia (Ph- ALL) has reported favorable results particularly in the younger subgroup of patients (pts) aged 18-40 years (Bassan et al, Blood Adv 2023). After the closure of the trial, this treatment scheme was adopted in the clinical practice by many Italian hematology centers for the treatment of newly diagnosed adult Ph- ALL. The safety of this intensive treatment in terms of infectious complications deserves to be investigated in the real life.

Aims To evaluate in the context of the real life the incidence of infectious complications in Ph- ALL pts treated off protocol according to the GIMEMA LAL1913 chemotherapy scheme and to assess the impact of the prophylactic measures adopted. **Methods** We retrospectively collected data on 178 Ph- ALL pts treated in 13 Italian hematology centers participating to the Campus ALL network in Italy. Pts were homogeneously treated following the GIMEMA LAL1913 scheme, but the use of anti-infective prophylaxis differed among centers and among cycles. We analyzed data with regard to the type and site of the infections, the cycles of treatment during which the infections occurred. Finally, we correlated the incidence of the infections with the presence or absence of anti-infective prophylaxis.

ONLINE PUBLICATION ONLY

Session 613

Results A total of 301 infectious events were diagnosed during the treatment of 134 of the 178 Ph- ALL pts (75%), including 98 episodes of fever of unknown origin (FUO) reported in 58 pts (33%). The distribution of the different types of documented infections for a total of 195 is reported in Table 1. The severity grading of infections (CTCAE.5) was available in 137 events and was \geq 3 in 101. SARS COV2 infection accounted for 22% of the viral infections (8/36 cases). We diagnosed 24 pulmonary infections (in 21 pts): 15 mycotic (13 probable and 2 possible), 6 bacterial and 3 viral infections. The number of pts undergoing an infection/cycle is shown in Table 2: 69 patients had at least one infection during cycle 1 (39% of treated pts); infections were mainly bacterial and occurred in prevalence during cycle 1. Two patients died of sepsis by Pseudomonas aeruginosa during cycle 1 (mortality rate: 1.1%). Pts receiving antibacterial prophylaxis were 94/178 (53%). Bacterial infections were reported in 47 pts receiving prophylaxis and in 41 pts who did not undergo prophylaxis; the difference between the two groups was not significant (p: 0.8). Patients receiving antifungal prophylaxis were 119/178 (67%). Mycotic infections were reported in 14 pts, and in 10 pts who did not receive prophylaxis; again, no significant difference was recorded between the two groups (p: 0.3). Patients receiving antiviral prophylaxis were 151/178 (85%). Viral infections were reported in 30 pts and in 4 pts not receiving prophylaxis; no statistical difference was observed (p: 0.4).

Summary/Conclusion The intensive GIMEMA LAL1913 treatment applied in the real life to newly diagnosed adult Ph-ALL pts is associated with a non-negligible rate of infections; >75% of treated pts suffered from at least one infection. Moreover, the large majority of these infections were severe with a CTCAE.5 grading \geq 3. However, the infection-related mortality was very low (1.%); the anti-infective treatment together with the achievement of a complete hematologic recovery were able to control and resolve the infectious complications. Bacterial infections were prevalent and bacteremias/sepsis represented 70% of events. Cycle 1 was most affected by infectious complications of all types; mycotic and viral infections were mostly reported during cycle 1, while they decreased markedly during the following cycles. Also incidence of bacterial events decreased during treatment, though they continued to occur also in the late phases of the management suggesting that a high level of attention should be maintained up to the end of treatment. Anti-infective prophylaxis was heterogeneously applied, but it remains unclear if it is necessary. The first analysis of this survey does not show an advantage of prophylaxis in reducing infections; however, particularly for fungal complications, the numbers are too limited to consider these results as conclusive. Data collection is still ongoing, and a larger sample size will allow more robust conclusions.

Disclosures Zappasodi: Amgen, Pfizer, Abbvie, Astellas: Honoraria. **Cerrano:** Insight Novartis Servier Abbvie Janssen Jazz Astellas Italfarmaco: Honoraria. **Fracchiolla:** Abbvie, Jazz, Pfizer, Amgen: Speakers Bureau; Abbvie, Jazz, Pfizer, Amgen: Other: travel grants. **Papayannidis:** Abbvie, Astellas, Servier, Menarini/Stemline, BMS, Pfizer, Amgen, Janssen, Incyte, Novartis: Honoraria; Pfizer, Astellas, Janssen, GSK, Blueprint, Jazz Pharmaceuticals, Abbvie, Novartis, Delbert Laboratoires: Membership on an entity's Board of Directors or advisory committees. **Chiaretti:** Incyte: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; *Abbvie:* Membership on an entity's Board of Directors or advisory committees; *Gilead:* Membership on an entity's Board of Directors or advisory committees; *Pfizer:* Membership on an entity's Board of Directors or advisory committees. **Candoni:** Abbvie: Honoraria; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Pfizer:* Honoraria; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Pfizer:* Honoraria; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Pfizer:* Honoraria; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Pfizer:* Honoraria; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Pfizer:* Honoraria; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Pfizer:* Honoraria; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees.

https://doi.org/10.1182/blood-2023-182976

Nasopharynx Documented Blood Soft Oral Other Urinary Lung Infections cavity tract tissue **Bacterial** 135 95 15 6 11 8 --Mycotic 24 13 8 4 ----3 Viral 36 3 15 3 12 --

Table 2: Infected patients and type of infections in the different cycles of treatment

Table 1: Type and site of documented infections

	C1	C2	C3	C4	C5	C6	C7	C8
Infected pts	69	23	20	12	4	17	16	7
Bacterial infections	51	21	19	6	4	16	14	4
Mycotic infections	18	3	. 8	2		1	-	8
Viral infections	22	3	1	4	u d	1	2	3

Figure 1